GRAIL, Inc. Reports Strong Q1 2026 Earnings with Growth in Test Volumes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 45 minutes ago
0mins
Should l Buy GRAL?
Source: seekingalpha
- Significant Sales Growth: GRAIL sold over 56,000 Galleri tests in Q1, driving total screening revenue to $39.8 million, reflecting continued strong physician adoption and health system engagement, thereby enhancing the company's competitive position in the cancer screening market.
- Strong Financial Performance: The total revenue for the first quarter was $40.8 million, with screening revenue up 37% year-over-year, indicating a significant increase in market demand, despite a net loss of $93.2 million, showcasing strong revenue growth potential.
- FDA Review Progress: The company has completed its FDA PMA submission, which has been accepted for review, expected to provide crucial support for the market launch of the Galleri test, further boosting investor confidence in future growth.
- Stable Future Outlook: Management reiterated the revenue growth expectation for 2026 to be between 22% and 32%, and despite market uncertainties, the integration of Epic Aura and expansion of the sales network are anticipated to effectively enhance market penetration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 55.660
Low
38.00
Averages
60.86
High
83.71
Current: 55.660
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL, Inc. Reports Strong Q1 2026 Earnings with Growth in Test Volumes
- Significant Sales Growth: GRAIL sold over 56,000 Galleri tests in Q1, driving total screening revenue to $39.8 million, reflecting continued strong physician adoption and health system engagement, thereby enhancing the company's competitive position in the cancer screening market.
- Strong Financial Performance: The total revenue for the first quarter was $40.8 million, with screening revenue up 37% year-over-year, indicating a significant increase in market demand, despite a net loss of $93.2 million, showcasing strong revenue growth potential.
- FDA Review Progress: The company has completed its FDA PMA submission, which has been accepted for review, expected to provide crucial support for the market launch of the Galleri test, further boosting investor confidence in future growth.
- Stable Future Outlook: Management reiterated the revenue growth expectation for 2026 to be between 22% and 32%, and despite market uncertainties, the integration of Epic Aura and expansion of the sales network are anticipated to effectively enhance market penetration.
See More
GRAIL Reports Q1 Earnings Beat Expectations
- Earnings Highlights: GRAIL's Q1 GAAP EPS of -$2.29 beats expectations by $0.47, indicating a positive trend in financial performance despite ongoing challenges.
- Revenue Growth: The company reported revenue of $40.8M, a 28.3% year-over-year increase, surpassing market expectations by $1.65M, reflecting sustained demand for its products and boosting market confidence.
- Improved Gross Loss: Gross loss was $14.3M, an improvement of $5.6M or 28% from the previous year, showcasing progress in cost control and operational efficiency.
- Cash Reserves: As of March 31, 2026, GRAIL's cash, cash equivalents, and short-term marketable securities totaled $823.1M, ensuring ample funding for future R&D and market expansion initiatives.
See More
GRAIL Presents NHS-Galleri Trial Results at ASCO 2026
- Large Participant Base: The NHS-Galleri trial and PATHFINDER 2 study enrolled over 174,000 participants, demonstrating the scientific rigor of the Galleri® multi-cancer early detection test, which is expected to significantly enhance the effectiveness of early cancer screening.
- Clinical Trial Design: The NHS-Galleri trial is the first randomized controlled study of an MCED test, designed to reduce late-stage cancer diagnoses through annual screening within England's National Health Service, thereby increasing early cancer detection rates.
- Data Presentation: GRAIL will present the complete dataset from the PATHFINDER 2 study, which includes over 32,000 evaluable participants, at the 2026 American Society of Clinical Oncology Annual Meeting, further validating the clinical utility and safety profile of the Galleri test.
- Market Potential: Dr. Josh Ofman highlighted that over 70% of cancer deaths in the U.S. are from cancers without recommended screening tests, and the introduction of the Galleri test is poised to change this landscape by improving the accessibility and effectiveness of early cancer detection.
See More
GRAIL Shares Decline After Neutral Ratings from Analysts
- Rating Downgrade Impact: GRAIL's shares fell on Friday after Mizuho Securities and Piper Sandler initiated coverage with Neutral ratings, indicating a decline in market confidence regarding its multi-cancer early detection test, Galleri.
- Trial Setback: The large clinical trial conducted within the U.K. National Health Service, involving over 140,000 participants, failed to meet its primary goal, which analysts suggest could hinder future competitive positioning in the market.
- Price Target Setting: Mizuho set a price target of $58, while Piper set it at $54, both expressing caution about Galleri's market outlook and suggesting that significant growth in MCED volume may not occur until 2027, post-FDA approval.
- Market Outlook Monitoring: Analysts noted that while GRAIL holds the largest clinical datasets in the multi-cancer early detection space, early feedback raises questions about its competitive advantage, making the evolution of reimbursement and regulatory pathways critical to watch.
See More
Investigation Launched into GRAIL, Inc. Securities Violations
- Investigation Initiated: The Schall Law Firm has announced an investigation into GRAIL, Inc. to determine potential violations of securities laws, particularly regarding whether the company issued false or misleading statements that could affect investor rights.
- Trial Results Disappoint: GRAIL's announcement on February 19, 2026, regarding the NHS-Galleri trial revealed that no statistically significant reduction in Stage III-IV was observed, leading to a sharp decline in the company's stock price and raising concerns about its future prospects.
- Investor Losses: Following the disappointing trial results, shareholders of GRAIL are facing potential losses, prompting the Schall Law Firm to encourage affected investors to participate in the investigation to protect their legal rights.
- Legal Services Offered: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering free consultations to assist global investors in addressing legal issues and safeguarding their investment interests.
See More
GRAIL Partners with Epic to Enhance Galleri Test Access
- Integration Advantage: GRAIL's collaboration with Epic will enable approximately 450 health systems to access Galleri test results within existing patient portals, streamlining the early cancer detection process and enhancing the efficiency and quality of healthcare services.
- Clinical Application Facilitation: The Epic Aura platform allows clinicians to seamlessly order the Galleri multi-cancer early detection test at the point of care, reducing administrative burdens and optimizing patient follow-up management, which is expected to significantly increase screening adoption rates.
- Implementation Planning Initiated: Implementation planning began in Q1 2026, with GRAIL working closely with Epic and AWS to ensure the success of early adopter programs, aiming for broad availability by the end of 2026 to further integrate early cancer screening.
- Survival Rate Improvement Goal: GRAIL aims to lower operational barriers through its partnership with Epic, making it easier to incorporate the Galleri test into routine care, ultimately supporting early cancer detection before symptoms appear and improving cancer survival rates.
See More
GRAIL, Inc. Reports Strong Q1 2026 Earnings with Growth in Test Volumes
- Significant Sales Growth: GRAIL sold over 56,000 Galleri tests in Q1, driving total screening revenue to $39.8 million, reflecting continued strong physician adoption and health system engagement, thereby enhancing the company's competitive position in the cancer screening market.
- Strong Financial Performance: The total revenue for the first quarter was $40.8 million, with screening revenue up 37% year-over-year, indicating a significant increase in market demand, despite a net loss of $93.2 million, showcasing strong revenue growth potential.
- FDA Review Progress: The company has completed its FDA PMA submission, which has been accepted for review, expected to provide crucial support for the market launch of the Galleri test, further boosting investor confidence in future growth.
- Stable Future Outlook: Management reiterated the revenue growth expectation for 2026 to be between 22% and 32%, and despite market uncertainties, the integration of Epic Aura and expansion of the sales network are anticipated to effectively enhance market penetration.
See More
GRAIL Reports Q1 Earnings Beat Expectations
- Earnings Highlights: GRAIL's Q1 GAAP EPS of -$2.29 beats expectations by $0.47, indicating a positive trend in financial performance despite ongoing challenges.
- Revenue Growth: The company reported revenue of $40.8M, a 28.3% year-over-year increase, surpassing market expectations by $1.65M, reflecting sustained demand for its products and boosting market confidence.
- Improved Gross Loss: Gross loss was $14.3M, an improvement of $5.6M or 28% from the previous year, showcasing progress in cost control and operational efficiency.
- Cash Reserves: As of March 31, 2026, GRAIL's cash, cash equivalents, and short-term marketable securities totaled $823.1M, ensuring ample funding for future R&D and market expansion initiatives.
See More
GRAIL Presents NHS-Galleri Trial Results at ASCO 2026
- Large Participant Base: The NHS-Galleri trial and PATHFINDER 2 study enrolled over 174,000 participants, demonstrating the scientific rigor of the Galleri® multi-cancer early detection test, which is expected to significantly enhance the effectiveness of early cancer screening.
- Clinical Trial Design: The NHS-Galleri trial is the first randomized controlled study of an MCED test, designed to reduce late-stage cancer diagnoses through annual screening within England's National Health Service, thereby increasing early cancer detection rates.
- Data Presentation: GRAIL will present the complete dataset from the PATHFINDER 2 study, which includes over 32,000 evaluable participants, at the 2026 American Society of Clinical Oncology Annual Meeting, further validating the clinical utility and safety profile of the Galleri test.
- Market Potential: Dr. Josh Ofman highlighted that over 70% of cancer deaths in the U.S. are from cancers without recommended screening tests, and the introduction of the Galleri test is poised to change this landscape by improving the accessibility and effectiveness of early cancer detection.
See More
GRAIL Shares Decline After Neutral Ratings from Analysts
- Rating Downgrade Impact: GRAIL's shares fell on Friday after Mizuho Securities and Piper Sandler initiated coverage with Neutral ratings, indicating a decline in market confidence regarding its multi-cancer early detection test, Galleri.
- Trial Setback: The large clinical trial conducted within the U.K. National Health Service, involving over 140,000 participants, failed to meet its primary goal, which analysts suggest could hinder future competitive positioning in the market.
- Price Target Setting: Mizuho set a price target of $58, while Piper set it at $54, both expressing caution about Galleri's market outlook and suggesting that significant growth in MCED volume may not occur until 2027, post-FDA approval.
- Market Outlook Monitoring: Analysts noted that while GRAIL holds the largest clinical datasets in the multi-cancer early detection space, early feedback raises questions about its competitive advantage, making the evolution of reimbursement and regulatory pathways critical to watch.
See More
Investigation Launched into GRAIL, Inc. Securities Violations
- Investigation Initiated: The Schall Law Firm has announced an investigation into GRAIL, Inc. to determine potential violations of securities laws, particularly regarding whether the company issued false or misleading statements that could affect investor rights.
- Trial Results Disappoint: GRAIL's announcement on February 19, 2026, regarding the NHS-Galleri trial revealed that no statistically significant reduction in Stage III-IV was observed, leading to a sharp decline in the company's stock price and raising concerns about its future prospects.
- Investor Losses: Following the disappointing trial results, shareholders of GRAIL are facing potential losses, prompting the Schall Law Firm to encourage affected investors to participate in the investigation to protect their legal rights.
- Legal Services Offered: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering free consultations to assist global investors in addressing legal issues and safeguarding their investment interests.
See More
GRAIL Partners with Epic to Enhance Galleri Test Access
- Integration Advantage: GRAIL's collaboration with Epic will enable approximately 450 health systems to access Galleri test results within existing patient portals, streamlining the early cancer detection process and enhancing the efficiency and quality of healthcare services.
- Clinical Application Facilitation: The Epic Aura platform allows clinicians to seamlessly order the Galleri multi-cancer early detection test at the point of care, reducing administrative burdens and optimizing patient follow-up management, which is expected to significantly increase screening adoption rates.
- Implementation Planning Initiated: Implementation planning began in Q1 2026, with GRAIL working closely with Epic and AWS to ensure the success of early adopter programs, aiming for broad availability by the end of 2026 to further integrate early cancer screening.
- Survival Rate Improvement Goal: GRAIL aims to lower operational barriers through its partnership with Epic, making it easier to incorporate the Galleri test into routine care, ultimately supporting early cancer detection before symptoms appear and improving cancer survival rates.
See More
